Immunology Drug Market to Witness a Handsome Growth during 2021 – 2026

The report entitled; “Immunology Drug Market, Trends, Dynamics, and Market Analysis,” recently published by Stratview Research offers a comprehensive outlook of the industry. This report byDrug Type (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication), By Application (Hospitals, Clinics, Cancer Research Centers and Institutes), and Region.

Global Immunology Drug Market Forecast:

The Immunology Drug market is projected to grow from USD 85.7 billion in 2020 to USD 135.8 billion by 2026 at a CAGR of around 8.2% during the forecast period.

Key Players

The following are some of the key players in the Immunology Drug Market:

  • Pfizer Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie, Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Merck Sharp & Dohme Corp. (U.S.)
  • Novartis AG (Switzerland)
  • Janssen Global Services, LLC (U.S.)
  • Amgen Inc. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • UCB SA (Belgium)

COVID-19 Impact on Global Immunology Drug Market

The COVID-19 pandemic is likely to favourably impact market growth. To curb the spread of the virus, countries worldwide are imposing restrictions and are promoting social distancing measures. Strict restrictions on the movement of people are further expected to negatively impact land-based casino operations.

Immunology Drug Market Segmentation:

The report segments based upon demographics, geographics, benefits and volume etc, has different driving factors and identifies the most-attractive segments and sub-segments. Immunology Drug Market segmentation will not only help marketers to be more efficient in terms of time, money and other resources but also allows companies to learn about their target audience so that they can tailor campaigns and increase market share and revenue.

By drug type, the immunology drug market has been classified into monoclonal antibodies (mAb), antibody-drug conjugates, interferon and cytokine therapies, immunosuppressive medication. Under these, the monoclonal antibodies (mAb) segment accounted for a significant market share in 2020 and is projected to register significant growth during the review period. This is mainly attributed to the rising number of approvals for mAb by the government bodies to treat chronic ailments across the globe, further fostering segment growth.

By region, the market in North America accounted for a significant market share in 2020 and is projected to grow at a significant CAGR during the assessment period. This is mainly ascribed to the rising prevalence of chronic ailments, robust healthcare infrastructure, the higher diagnosis rate of the patients, increasing healthcare expenditure, and a large number of home healthcare facilities, which further proliferates the regional market growth.

For inquiries, Contact:

Ritesh Gandecha

Stratview Research


Direct: +1-313-307-4176

About Stratview Research
Stratview Research is a global market intelligence firm helping its clients’ tract the ever-evolving market scenarios through customised and syndicated reports. The reports offered here are gathered with the help of our wide-ranging and reliable secondary sources and in-depth interviews with the linchpins within the market. Extrapolated through primary and secondary research, Stratview Research’s reports help you remain ahead of the curve by enabling you to understand the current market trends and challenges coming on your way. Our strong team of industry veterans and researchers assure high quality research and strategic insights that help companies worldwide in effective decision making.

One thought on “Immunology Drug Market to Witness a Handsome Growth during 2021 – 2026

Leave a Reply

Your email address will not be published. Required fields are marked *